Partners seeks innovators for Connected Health Challenge

The 2016 Partners Connected Health Innovation Challenge is now accepting applications.

The challenge seeks to identify novel ideas addressing a current concern in preventive care or chronic disease management, according to an announcement letter written by Partners' Chief Clinical Officer Gregg S. Meyer, MD, MSc. "We welcome proposals featuring technology-enabled solutions that facilitate and/or enhance the delivery of care beyond the clinical settings. The proposed idea may include a device, mobile-based application or any other technology-enabled approach."

The grand prize winner will receive support to develop their idea from vision to initial pilot through the provision of expert services, which is estimated at $150,000, including user-centerred design, full technology development and protocol design to implement a pilot study. Seven other individuals or teams will be selected to receive either full services from the Partners User Centered Design team, valued at $40,000, and/or an opportunity to present a poster at the 2016 Connected Health Symposium.

The challenge is a joint effort between Partners HealthCare Connected Health and the Journal of Medical Internet Research.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.